[13C6]-Mitotan metabolite

[13C6]-Mitotan metabolite, also known as 13C6-Lysomidotan, is a stable isotope-labeled metabolite of mitotane, a chemotherapeutic agent used in the treatment of adrenal cancer. It is mainly used as a reference standard in various analytical and clinical chemistry applications. The metabolite contains 13 carbon atoms, six of which are stable isotopes of carbon-13, and is synthesized by labeling mitotane with stable isotope carbon-13. The labeling allows for the detection and quantification of mitotane metabolites using mass spectrometry, a highly sensitive analytical technique. In terms of usage, [13C6]-Mitotan metabolite is primarily used as an internal standard in analytical methods for the quantification of mitotane metabolites in biological samples, such as plasma and urine. It is also used in clinical chemistry applications to monitor the effectiveness of mitotane therapy and to assess patient compliance with treatment. Chemically, [13C6]-Mitotan metabolite is a derivative of mitotane, which is a chlorinated hydrocarbon compound. Mitotane works by selectively destroying the adrenal cortex, which is responsible for producing hormones, including cortisol. However, the use of mitotane is associated with a high risk of adverse effects, including liver toxicity, neurological complications, and endocrine dysfunction. In conclusion, [13C6]-Mitotan metabolite is a stable isotope-labeled metabolite of mitotane that is mainly used as a reference standard in analytical and clinical chemistry applications. Its chemical properties and labeling allow for the sensitive detection and quantification of mitotane metabolites, making it a valuable tool in the monitoring of mitotane therapy.